CMR 2005: 7.04: Hemoglobin, a physiological contrast medium for optical molecular imaging of the female breast: computed tomography–laser mammography in the differentiation of benign and malignant breast lesions

2006 ◽  
Vol 1 (2) ◽  
pp. 71-71
Author(s):  
T.H. Helbich ◽  
C. C. Riedl ◽  
S. Jaromi ◽  
M.H. Fuchsjaeger ◽  
C. Reiner ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Molecular Imaging ◽  
Contrast Medium ◽  
Breast Lesions ◽  
Optical Molecular Imaging ◽  
Female Breast ◽  
Hemoglobin A ◽  
Malignant Breast ◽  
Breast Computed Tomography

Evaluation of Malignant Breast Lesions in the Diagnostic Setting with Cone Beam Breast Computed Tomography (Breast CT): Feasibility Study

2014 ◽  
Vol 20 (4) ◽  
pp. 364-374 ◽  
Author(s):  
Posy Seifert ◽  
David Conover ◽  
Yan Zhang ◽  
Renee Morgan ◽  
Andrea Arieno ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Feasibility Study ◽  
Cone Beam ◽  
Breast Lesions ◽  
Breast Ct ◽  
Malignant Breast ◽  
Diagnostic Setting ◽  
Breast Computed Tomography

scholarly journals Dedicated Cone-beam Breast Computed Tomography and Diagnostic Mammography: Comparison of Radiation Dose, Patient Comfort, And Qualitative Review of Imaging Findings in BI-RADS 4 and 5 Lesions

2012 ◽  
Vol 2 ◽  
pp. 7 ◽  
Author(s):  
Avice M. O’Connell ◽  
Daniel Kawakyu-O’Connor
Keyword(s):  
Computed Tomography ◽  
Radiation Dose ◽  
Breast Imaging ◽  
Qualitative Evaluation ◽  
Patient Comfort ◽  
Cone Beam ◽  
Breast Lesions ◽  
Diagnostic Mammography ◽  
High Degree ◽  
Breast Computed Tomography

Objective: This pilot study was undertaken to compare radiation dose, relative visibility/conspicuity of biopsy-proven lesions, and relative patient comfort in diagnostic mammography and dedicated cone-beam breast computed tomography (CBBCT) in Breast Imaging-Reporting and Data System (BI-RADS)® 4 or 5 lesions. Materials and Methods: Thirty-six consecutive patients (37 breasts) with abnormal mammographic and/or ultrasound categorized as BI-RADS® 4 or 5 lesions were evaluated with CBBCT prior to biopsy. Administered radiation dose was calculated for each modality. Mammograms and CBBCT images were compared side-by-side and lesion visibility/conspicuity was qualitatively scored. Histopathology of lesions was reviewed. Patients were administered a survey for qualitative evaluation of comfort between the two modalities. Results: CBBCT dose was similar to or less than diagnostic mammography, with a mean dose of 9.4 mGy (±3.1 SD) for CBBCT vs. 16.9 mGy (±6.9 SD) for diagnostic mammography in a total of 37 imaged breasts (P<0.001). Thirty-three of 34 mammographic lesions were scored as equally or better visualized in CBBCT relative to diagnostic mammography. Characterization of high-risk lesions was excellent. Patients reported greater comfort in CBBCT imaging relative to mammography. Conclusion: Our experience of side-by-side comparison of CBBCT and diagnostic mammography in BI-RADS® 4 and 5 breast lesions demonstrated a high degree of correlation between the two modalities across a variety of lesion types. Owing to favorable radiation dose profile, excellent visualization of lesions, and qualitative benefits including improved patient comfort, excellent field-of-view, and more anatomical evaluation of lesion margins, CBBCT offers a promising modality for diagnostic evaluation of breast lesions.

scholarly journals Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results

2017 ◽  
Vol 35 (19) ◽  
pp. 2133-2140 ◽  
Author(s):  
Jürgen K. Willmann ◽  
Lorenzo Bonomo ◽  
Antonia Carla Testa ◽  
Pierluigi Rinaldi ◽  
Guido Rindi ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Gold Standard ◽  
Breast Lesions ◽  
Clinical Grade ◽  
Human Clinical Trial ◽  
Before And After ◽  
Malignant Breast ◽  
Malignant Lesions ◽  
Ultrasound Molecular Imaging ◽  
Benign Breast Lesions

Purpose We performed a first-in-human clinical trial on ultrasound molecular imaging (USMI) in patients with breast and ovarian lesions using a clinical-grade contrast agent (kinase insert domain receptor [KDR] –targeted contrast microbubble [MBKDR]) that is targeted at the KDR, one of the key regulators of neoangiogenesis in cancer. The aim of this study was to assess whether USMI using MBKDR is safe and allows assessment of KDR expression using immunohistochemistry (IHC) as the gold standard. Methods Twenty-four women (age 48 to 79 years) with focal ovarian lesions and 21 women (age 34 to 66 years) with focal breast lesions were injected intravenously with MBKDR (0.03 to 0.08 mL/kg of body weight), and USMI of the lesions was performed starting 5 minutes after injection up to 29 minutes. Blood pressure, ECG, oxygen levels, heart rate, CBC, and metabolic panel were obtained before and after MBKDR administration. Persistent focal MBKDR binding on USMI was assessed. Patients underwent surgical resection of the target lesions, and tissues were stained for CD31 and KDR by IHC. Results USMI with MBKDR was well tolerated by all patients without safety concerns. Among the 40 patients included in the analysis, KDR expression on IHC matched well with imaging signal on USMI in 93% of breast and 85% of ovarian malignant lesions. Strong KDR-targeted USMI signal was present in 77% of malignant ovarian lesions, with no targeted signal seen in 78% of benign ovarian lesions. Similarly, strong targeted signal was seen in 93% of malignant breast lesions with no targeted signal present in 67% of benign breast lesions. Conclusion USMI with MBKDR is clinically feasible and safe, and KDR-targeted USMI signal matches well with KDR expression on IHC. This study lays the foundation for a new field of clinical USMI in cancer.

Characterization of Benign and Malignant Breast Lesions With Computed Tomography Laser Mammography (CTLM)

2005 ◽  
Vol 40 (6) ◽  
pp. 328-335 ◽  
Author(s):  
Daniel Floery ◽  
Thomas H. Helbich ◽  
Christopher C. Riedl ◽  
Silvia Jaromi ◽  
Michael Weber ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Breast Lesions ◽  
Malignant Breast

scholarly journals Neutrosophic segmentation of breast lesions for dedicated breast computed tomography

2018 ◽  
Vol 5 (01) ◽  
pp. 1 ◽  
Author(s):  
Juhun Lee ◽  
Robert M. Nishikawa ◽  
Ingrid Reiser ◽  
John M. Boone
Keyword(s):  
Computed Tomography ◽  
Breast Lesions ◽  
Breast Computed Tomography

201Tl Scintigraphy in the Evaluation of Palpable and Nonpalpable Breast Lesions: Correlation with Mammography and Ultrasonography

1997 ◽  
Vol 36 (08) ◽  
pp. 282-288 ◽  
Author(s):  
T. Atasever ◽  
A. Özdemir ◽  
I. Öznur ◽  
N. I. Karabacak ◽  
N. Gökçora ◽  
...  
Keyword(s):  
Final Diagnosis ◽  
Lower Sensitivity ◽  
Breast Lesions ◽  
Breast Cancers ◽  
Combined Use ◽  
Malignant Breast ◽  
Malignant Lesions ◽  
Benign Breast Lesions ◽  
Palpable Breast ◽  
Metastatic Sites

Summary Aim: Our goal was to determine the clinical usefulness of TI-201 to identify breast cancer in patients with suspicious breast lesions on clinical examination, and/or abnormal radiologic (mammography and/or ultrasonography) findings. Methods: TI-201 scintigraphy were performed in sixty-eight patients with 70 breast abnormalities (51 palpable, 19 nonpalpable) and compared with mammography and ultrasonography (US). Early (15 min) and late (3 h) images of the breasts were obtained following the injection of 111 MBq (3 mCi) of TI-201. Visual and semiquantitative interpretation was performed. Results: Final diagnosis confirmed 52 malignant breast lesions and 18 benign conditions. TI-201 visualized 47 of 52 (90%) overall malignant lesions. Thirty-eight of 40 (95%) palpable and 9 of 12 (75%) nonpalpable breast cancers were detected by TI-201 scintigraphy. The smallest mass lesion detected by TI-201 measured 1.5x1.0 cm. Eleven breast lesions were interpreted as indeterminate by mammography and/or sonography. TI-201 scintigraphy excluded malignancy in 7 of 8 (88%) patients with benign breast lesions interpreted as indeterminate. Five of the 18 (28%) benign breast lesions showed TI-201 uptake. None of the fibroadenoma and fibrocystic changes accumulated TI-201. TI-201 scintigraphy, mammography and ultrasonography showed 90%, 92%, 85% overall sensitivity and 72%, 56%, 61% overall specificity respectively. Twenty-one of the 28 (75%) axillary nodal metastatic sites were also detected by TI-201. In malignant and benign lesions, early and late lesion/contralateral normal side (L/N) ratios were 1.58 ± 0.38 (mean ± SD) and 1.48 ± 0.32 (p >0.05), 1.87 ± 0.65 and 1.34 ± 0.20 (p<0.05) respectively. The mean early and late L/N ratios of malignant and benign groups did not show statistical difference (p>0.05). Conclusion: Overall, TI-201 scintigraphy was the most specific of the three methods and yielded favourable results in palpable breast cancers, while it showed lower sensitivity in nonpalpable cancers and axillary metastases. Combined use of TI-201 scintigraphy with mammography and US seems to be useful in difficult cases, such as dense breasts and indeterminate breast lesions.

Amplification of HER-2 Gene in Benign and Malignant Breast Lesions in a Sample of Iraqi Women

2017 ◽  
Vol 13 (2) ◽  
pp. 35-39
Author(s):  
Maysoon Abdul-Ameer Ahmed Al-Salman ◽  
◽  
Risala Hussain Allami ◽  
Lamyaa H. M. Al-Ibrahimi
Keyword(s):  
Breast Lesions ◽  
Malignant Breast ◽  
Iraqi Women ◽  
Her 2
Sign in / Sign up

Export Citation Format

Share Document